OC Precision Medicine embraces the Pathologic Anatomy, Genomics and Big Data labs, offering a complete molecular portfolio of high clinical relevance for diagnostic, predictive and prognostic purposes, effectively contributing to the prevention and treatment of patients.
In the molecular conferences, the main pathologic and genomic tests recommended for each tumor type are detailed, and it can direct more assertive clinical decisions that include targeted therapies and immunotherapies, increasing the response probability.
GS180 is the sequencing panel that analyzes changes in tumor DNA and RNA sequence, such as mutations. Detecting changes that affect the function of particular genes indicates opportunities for treatment with targeted drugs or immunotherapy.
Germinative tests analyze genes associated with hereditary predisposition to several types of cancer. It is a very valuable prevention tool and, in several cases, can also help in the clinical management of patients who have already developed cancer.
Pathologic Anatomy in Precision Medicine integrates microscopic findings with data from genomic testing, providing anatomopathological data to guide clinical decisions.
Our diagnostic tests are performed by a technical staff that combines high precision, technology and innovation in three stages: pathology, genomics and protocols/therapies target.
We have gathered the most effective cancer treatments combined with scientific innovations in oncology
